Refractory Metastatic Melanoma Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in Refractory Metastatic Melanoma Research. Learn more about our innovative pipeline today! @ Refractory Metastatic Melanoma Pipeline Outlook
Key Takeaways from the Refractory Metastatic Melanoma Pipeline Report
In July 2025, Genmab announced clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo.
DelveInsight's Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Refractory Metastatic Melanoma treatment.
The leading Refractory Metastatic Melanoma Companies such as BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others.
Promising Refractory Metastatic Melanoma Pipeline Therapies such as GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others.
Stay informed about the cutting-edge advancements in Refractory Metastatic Melanoma treatments. Download for updates and be a part of the revolution in Dermatology care @ Refractory Metastatic Melanoma Clinical Trials Assessment
Refractory Metastatic Melanoma Emerging Drugs Profile
BNT111: BioNTech SE
BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens aiming to trigger a strong and precise immune response in patients with anti-PD-(L) 1 refractory/relapsed, unresectable Stage III or IV melanoma. BNT111 is an mRNA-based off-the-shelf cancer immunotherapy candidate for intravenous administration encoding a fixed set of four non-mutated melanoma-associated antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) delivered as uridine mRNA-lipoplex formulation. Over 90% of patients with cutaneous melanomas express at least one of these antigens. The BNT111 program has also received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration. Currently, the drug is in Phase II stage of its development for the treatment of Refractory Metastatic Melanoma.
GD2-SADA: Y-mAbs Therapeutics
The GD2-SADA construct is created using SADA technology, that utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target. Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs attached to the tumor target in order to radiate the tumor. This provides the possibility of targeting tumors with precision while minimizing radiation of normal tissues. The SADA technology platform can deliver a variety of payloads and could potentially be developed against multiple tumor targets, as well as for theragnostic purposes. Currently, the drug is in Phase I stage of its development for the treatment of Refractory Metastatic Melanoma.
The Refractory Metastatic Melanoma Pipeline Report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Metastatic Melanoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Metastatic Melanoma Treatment.
Refractory Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Refractory Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Metastatic Melanoma market.
Learn more about Refractory Metastatic Melanoma Drugs opportunities in our groundbreaking Refractory Metastatic Melanoma research and development projects @ Refractory Metastatic Melanoma Unmet Needs
Refractory Metastatic Melanoma Companies
BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others.
Refractory Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Refractory Metastatic Melanoma Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in Refractory Metastatic Melanoma treatment by visiting our website. Stay informed about how we're transforming the future of dermatology @ Refractory Metastatic Melanoma Market Drivers and Barriers, and Future Perspectives
Scope of the Refractory Metastatic Melanoma Pipeline Report
Coverage- Global
Refractory Metastatic Melanoma Companies- BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others.
Refractory Metastatic Melanoma Pipeline Therapies- GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others.
Refractory Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Refractory Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Refractory Metastatic Melanoma Pipeline on our website @ Refractory Metastatic Melanoma Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Refractory Metastatic Melanoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Refractory Metastatic Melanoma – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Refractory Metastatic Melanoma Collaboration Deals
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BNT111: BioNTech SE
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
GD2-SADA: Y-mAbs Therapeutics
Drug profiles in the detailed report…
Pre-clinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Refractory Metastatic Melanoma Key Companies
Refractory Metastatic Melanoma Key Products
Refractory Metastatic Melanoma- Unmet Needs
Refractory Metastatic Melanoma- Market Drivers and Barriers
Refractory Metastatic Melanoma- Future Perspectives and Conclusion
Refractory Metastatic Melanoma Analyst Views
Refractory Metastatic Melanoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/refractory-metastatic-melanoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
23 minutes ago
- Globe and Mail
Healthcare Triangle Surges Forward: QuantumNexis's AI-Driven HIMS Platform 'Ezovion' Now Live on Microsoft Azure Marketplace
PLEASANTON, CA - August 1, 2025 (NEWMEDIAWIRE) - Healthcare Triangle, Inc. (Nasdaq: HCTI) ('HCTI' or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries - today announced a major milestone: its wholly owned subsidiary, QuantumNexis, has launched its AI-powered Hospital Information Management System (HIMS), Ezovion, on the Microsoft Azure Marketplace. This strategic move enhances Ezovion's accessibility to global healthcare providers and positions HCTI for expanded commercial growth through a trusted, enterprise-grade cloud platform. Ezovion is an advanced, cloud-native HIMS platform designed to digitize and optimize clinical, administrative, and operational workflows. From patient registration to billing, diagnostics, EMR integration, and mobile health enablement, Ezovion delivers intelligent automation that reduces costs, enhances care delivery, and drives operational efficiency. "Microsoft Azure Marketplace welcomes Ezovion Digital Healthcare Solutions, which joins a cloud marketplace landscape offering flexibility and economic value while transacting tens of billions of dollars a year in revenues," said Jake Zborowski, General Manager, Microsoft Azure Platform at Microsoft Corp. "Thanks to Azure Marketplace and partners like Ezovion, customers can do more with less by increasing efficiency, buying confidently, and spending smarter." By launching on Azure Marketplace, Ezovion now offers: This move aligns with HCTI's broader innovation roadmap, which includes GenAI-powered platforms such as Ziloy for mental wellness and for intelligent medical data automation - positioning the company as a high-impact, Nasdaq-listed digital health leader driving next-generation solutions across the care continuum. About Healthcare Triangle Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare organizations including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz™ and DataEz™. HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical & business performance optimization. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995), and include, among others, statements regarding the consummation of the private placement, satisfaction of the customary closing conditions of the private placement and the use of the proceeds therefrom. Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, on file with the Securities Exchange Commission (the 'SEC') and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
National Post
23 minutes ago
- National Post
CORTEC Announces Acquisition of Houston-based Power Chokes™ from ADS Services
Article content HOUMA, La. — CORTEC, an internationally established U. S. manufacturer of choke, valve and automation products, announced today that it has acquired Power Chokes™ – a long-standing, prominent manufacturer of chokes and pressure control equipment – from ADS Services, a Black Bay Partners portfolio company. This acquisition includes the Power Chokes manufacturing division and all intellectual property associated with legacy Power Chokes equipment. Article content Established in 1988, Power Chokes has been a widely recognized, high-quality manufacturer of pressure control products and services for the oil and gas industry, including well control chokes, managed pressure drilling (MPD) chokes and pressure relief systems. Power Chokes has maintained a global presence for over 30 years, serving drilling contractors, operators and service companies across the industry. Article content This strategic acquisition strengthens CORTEC's commitment to cementing itself as the clear leader in manufacturing choke, valve and associated automation solutions for the global energy industry. By integrating Power Chokes' well-established base of chokes and pressure control equipment, this move significantly broadens CORTEC's footprint and expands its already extensive lineup of offerings for the worldwide energy sector. Article content 'Our team is excited to incorporate the Power Chokes brand and products into an expanding lineup of pressure control equipment offerings. This acquisition joins two leading brands in the well control choke and control systems market, combining a rich legacy of reliability and service within our sector,' said Bobby Corte Jr., CEO of CORTEC. 'We are honored to take custody of this long-established company and to instill the values, consistent quality and high reliability that the CORTEC brand is known for. We welcome the Power Chokes employees, customers and strategic partners to join us in this new, exciting chapter of our company.' Article content 'I want to thank the Power Chokes employees, customers and suppliers for years of dedication to the Power Chokes business. The team at CORTEC is perfectly situated to foster and continue to grow and support our product offerings. The ADS Services team looks forward to collaborating with CORTEC on our core managed pressure drilling business and the new product lines we are rolling out in the coming months,' said Charlie Orbell, CEO of ADS Services. Article content About CORTEC Article content Founded in January 2004, CORTEC is an internationally established US manufacturer of choke, valve and automation products suited to a range of global energy industry applications across upstream, midstream and downstream markets. CORTEC is a privately owned, vertically integrated organization comprised of two divisions, CORTEC Fluid Control (CFC) and CORTEC Manifold Systems (CMS). It engineers, manufactures, assembles and tests its products in Louisiana, USA under API 6A, 6D and 16C licenses with a quality system registered in accordance with API Q1 and ISO 9001. Article content About ADS Services Article content Based in the heart of the Permian Basin, ADS Services delivers cutting-edge managed pressure drilling (MPD) solutions that keep oil and gas drilling operations safe and efficient. The ADS management team has fostered MPD development for decades, and the company has delivered next-generation MPD solutions for US onshore and international operators. ADS has an operational base in Midland (TX) and a manufacturing and training base in Odessa (TX). ADS Services is a Black Bay Partners portfolio company. Article content Article content Article content Article content Contacts Article content MEDIA: Article content Article content Kristi Moore Article content Article content CORTEC Marketing Article content Article content Article content
Globe and Mail
23 minutes ago
- Globe and Mail
US employers added just 73,000 jobs last month as labor market weakens in face of Trump trade wars
WASHINGTON (AP) — U.S. employers added just 73,000 jobs last month and Labor Department revisions showed that hiring was much weaker than previously reported in May and June. The unemployment rate ticked up to 4.2%. The deterioration in the job market is taking place with companies paralyzed by uncertainty over President Donald Trump's erratic trade policies. The Labor Department reported Friday that revisions shaved a stunning 258,000 jobs off May and June payrolls. The stock market tumbled on the news. THIS IS A BREAKING NEWS UPDATE. AP's earlier story follows below. WASHINGTON (AP) — The American job market is deteriorating -- ever so slowly. It's not showing up as widespread layoffs. The unemployment rate is still low. It's subtler than that: New college graduates are struggling to break into the job market. The unemployment rate for college graduates 22 to 27 years old, reached 5.8% in March, the highest, excluding the pandemic, since 2012, and far above the nationwide unemployment rate. Many Americans are staying in their jobs, unwilling to start the job hunt, because they believe this is as good as it gets, and there is growing evidence that they're right: Few industries are actually hiring aggressively. The current situation is a sharp reversal from the hiring boom of just three years ago when desperate employers were handing out signing bonuses and introducing perks such as Fridays off, fertility benefits and even pet insurance to recruit and keep workers. When the Labor Department puts out its July employment report Friday, it's expected to show that companies, government agencies and nonprofits collectively added 115,000 jobs last month, according to a survey of forecasters by the data firm FactSet. That is not a bad number but its worse than last year, and even last month, when employers added 147,000 jobs. Employers added an average 130,000 jobs a month through June, down 23% from last year's hiring and a whopping 68% below the 2021-2023 average when the economy was bounding back from COVID-19 lockdowns. Weighing on the job market are the lingering effects of higher interest rates that were used by the Federal Reserve to fight inflation; President Donald Trump's massive import taxes and the costs and uncertainty they are imposing on businesses; and an anticipated drop in foreign workers as the president's massive deportation plans move forward. 'The labor market is poised for a summer slowdown as businesses put hiring plans on hold but refrain from broad-based layoffs,' Gregory Daco, chief economist at EY-Parthenon wrote in a commentary this week. 'We see job growth slowing well below trend in the coming months.'' Still, most American workers enjoy an unusual level of job security. The unemployment rate is low at 4.1%. The number of Americans applying for unemployment benefits — a proxy for layoffs — remains at healthy levels. But Adam Schickling, senior economist at Vanguard, cautions that 'a low unemployment rate and a muted pace of layoffs mask underlying weakness.'' In a commentary Tuesday, Schickling wrote that the health of the job market 'can be a matter of individual you're a registered nurse, you may believe the job market's health to be excellent. The unemployment rate for experienced health care practitioners is currently below 2%. If you're young and just entering the labor force or you're older and seeking to reenter it, prospects may seem bleak.'' The rate of people quitting their jobs — a sign they're confident they can land something better — has fallen from the record heights of 2021 and 2022 and is now below where it stood before the pandemic. For one thing, hiring has become concentrated in a handful of industries. So far this year, for example, private U.S. employers have added 644,000 jobs. Of those, nearly 405,000 — or 63% — were in just one of the Labor Department's industry categories: healthcare and social assistance, which spans everything from hospitals to daycare centers. As hiring has cooled over the past couple of years it's become harder for young people or those re-entering the workforce to find jobs, leading to longer job searches or spells of unemployment. The Labor Department said the number of discouraged workers, who believe no jobs are available for them, rose by 256,000 in June to 637,000. 'Historically, a decline in hiring has been accompanied by a swift rise in layoffs, a one-two punch that drives up the unemployment rate,' Schickling wrote in a commentary. 'Today's labor market is defying that pattern.'' One reason is that manufacturing companies, which tend to pull the trigger on layoffs quickly when economic conditions weaken, account for an ever-smaller share of American jobs. 'So there is simply less headcount to cut,'' he said. The bottom line: 'Firms are pulling back on hiring without shedding existing workers in significant numbers,'' Schickling said. 'The result is a labor market that is softening gradually, not collapsing.''
